KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) Research & Development (2016 - 2025)

Cme (CME) has disclosed Research & Development for 17 consecutive years, with $75.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 14.46% to $75.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $283.2 million, a 10.71% increase, with the full-year FY2025 number at $283.2 million, up 10.71% from a year prior.
  • Research & Development was $75.2 million for Q4 2025 at Cme, up from $71.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $75.2 million in Q4 2025 to a low of $45.8 million in Q4 2021.
  • A 5-year average of $56.9 million and a median of $54.4 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: dropped 14.55% in 2021, then grew 20.26% in 2024.
  • Cme's Research & Development stood at $45.8 million in 2021, then rose by 9.17% to $50.0 million in 2022, then increased by 17.0% to $58.5 million in 2023, then increased by 12.31% to $65.7 million in 2024, then grew by 14.46% to $75.2 million in 2025.
  • Per Business Quant, the three most recent readings for CME's Research & Development are $75.2 million (Q4 2025), $71.4 million (Q3 2025), and $70.9 million (Q2 2025).